Supernus Pharmaceuticals Inc Earnings Dividend

Supernus Pharmaceuticals Inc’s revenue jumped 21.48% since last year same period to $211.57Mn in the Q4 2025. On a quarterly growth basis, Supernus Pharmaceuticals Inc has generated 10.13% jump in its revenue since last 3-months.

Supernus Pharmaceuticals Inc’s net profit fell -126.78% since last year same period to $-4.11Mn in the Q4 2025. On a quarterly growth basis, Supernus Pharmaceuticals Inc has generated 90.9% jump in its net profits since last 3-months.

Supernus Pharmaceuticals Inc’s net profit margin fell -122.05% since last year same period to -1.94% in the Q4 2025. On a quarterly growth basis, Supernus Pharmaceuticals Inc has generated 91.74% jump in its net profit margins since last 3-months.

Supernus Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at 0.41 - a 192.86% jump from last quarter’s estimates.

Supernus Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at 0.41.

Supernus Pharmaceuticals Inc’s earning per share (EPS) jumped 60.88% since last year same period to 0.88 in the Q4 2025. This indicates that the Supernus Pharmaceuticals Inc has generated 60.88% annual rate of jump in its earning per share (EPS) in the last 4 quarters.